Online inquiry

IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11983MR)

This product GTTS-WQ11983MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ERBB3&IGF1R gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1; NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065; 3480
UniProt ID P21860; P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11983MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4594MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ1247MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ6672MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ13988MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ8149MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ1212MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ7398MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ7909MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW